WHO: 2nd National Consultation On The Use Of The Antiretroviral Pre-Exposure Prophylaxis (PrEP) To Prevent HIV Acquisition In Malaysia

Project Timeline

2018 – 2019

The Second National Consultation on the Use of Antiretroviral Pre-exposure Prophylaxis (PrEP) to Prevent HIV Acquisition was held in Kuala Lumpur, Malaysia, on 4 June 2018. The consultation was convened by the Centre of Excellence for Research in AIDS (CERiA) at the University of Malaya, the Malaysian AIDS Council (MAC) and the World Health Organization (WHO) to follow up on recommendations by the first national PrEP consultation held in May 2016.The purpose was to stimulate further dialogue and discussion among various stakeholders involved in the implementation and scale up of PrEP in Malaysia and to learn from the experience of other Asian countries. Participants included members of community-based organizations (CBOs), infectious disease physicians, primary care doctors, researchers, Ministry of Health officials, PrEP users, civil society representatives and international experts.

External Links

Second National Consultation on the Use of Antiretroviral Pre-exposure Prophylaxis (PrEP) to Prevent HIV Acquisition, 4 June 2018, Kuala Lumpur, Malaysia : Meeting Report

Events

Other Clinical Research

Strategic Timing of Anti-Retroviral Treatment (START Study)

The START trial was designed to address the question: In HIV-1 (subsequently referred to as HIV) infected asymptomatic participants with a CD4+ count greater than 500 cells/mm3, is immediate use...

Making Drug Treatment Work: Opportunities and Challenges Towards an Evidence and Rights-Based Approach

Compulsory drug detention centers (CDDCs) are common throughout Asia. However, medical treatments for substance use disorders, such as opioid agonist treatment (OAT), are generally unavailable in these settings. In this...

Dolutegravir and Darunavir Evaluation in Adults Failing Therapy (D²EFT)

First-line antiretroviral regimens are safe, effective and easily administered (one pill taken once daily). Even so, the annual failure rate is around 10-15% of treated patients. Second-line regimens have a...